Infusion of iloprost without a peristaltic pump: Safety and tolerability;Sicurezza e tollerabilita della somministrazione di iloprost senza pompa peristaltica

Italian Journal of Medicine

Volumn 4, Issue 3, 2010, Pages 179-184

  Faggioli, Paola ^a   Giani, Leopoldo ^a   Mazzone, Antonino ^a  

^a Ospedale Civile di Legnano   (Italy)

Author keywords

Iloprost; Infusion related adverse events; Peripheral arterial disease; Peristaltic pump; Safety; Systemic sclerosis

Indexed keywords

ILOPROST; PROSTANOID;

ARTICLE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; EXTRASYSTOLE; FLOW RATE; HEART ARRHYTHMIA; HOSPITALIZATION; HUMAN; HYPERTENSION; HYPOTENSION; INTENSIVE CARE; MAJOR CLINICAL STUDY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERISTALTIC PUMP; RETROSPECTIVE STUDY; SIDE EFFECT; SYSTEMIC SCLEROSIS; TACHYCARDIA; UNSPECIFIED SIDE EFFECT;

EID: 79957935133     PISSN: 18779344     EISSN: 18779352     Source Type: Journal    
DOI: 10.1016/j.itjm.2010.04.005     Document Type: Article

References (29)

1. Wada M, Yokoyama C, Hatae T, Shimonishi M, Nakamura M, Imal Y, et al. Purification and characterization of recombinat human prostacyclin syntase. J Biochem 2004;135(4):455-63. (Pubitemid 38660931)
2. Lim H, Dey SK. Minireview: a novel pathway of prostacyclin signaling-hanging out with nuclear receptors. Endocrinology 2002;143(9):3207-10. (Pubitemid 34925693)
3. Liou JY, Shyue SK, Tsai MJ, Chung CL, Chu KY, Wu KK. Colocation of prostacyclin synthase with prostaglandin H-synthase 1 but not phorbol ester-induced PGHS-2 in cultured endothelial cells. J Biol Chem 2000;19:15314-20. (Pubitemid 30337258)
4. Narumiya P, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties and functions. Physiol Rev 1999;79:1193-226. (Pubitemid 29473315)
5. Funk CD. Prostaglandins and leukotriens: advances in eicosanoid biology. Science 2001;294:18721-5.
6. Katsuyama M, Surgimoto Y, Namba T, Irie A, Negishi M, Narumiya S, et al. Clonig and expression of c-DNA for the human prosta-cyclin receptor. FEBS lett 1994;344:74-8.
7. Pola R, Gaetani E, Flex A, et al. Comparative anlysis of the in vivo angiogenic properties of stable prostacyclin analogs: a possible role for peroxisome prolipherator activated receptors. J Mol Cell Cardiol 2004;36:363-70. (Pubitemid 38316941)
8. Toshihisa H, Masayuki W, Yokoyama C, Shimonishi M, Tanabe T. Prostacyclin dependent apoptosis mediated by PPAR. J Biol Chem 2001;276:46260-7.
9. Banyai S, Jenelten R, Wagner S, Allmann J, Banyai M, Koppensteiner R. Outpatient treatment of severe peripheral ischemia with intravenous intermittent low dose iloprost. An open pilot study. Int Angiol 2002;21:36-43. (Pubitemid 34413652)
10. Cipollone F, Fazia M, Mincione G, Iezzi A, Pini B, Cuccurullo F, et al. Increased expression of Transforming Growth Factor-beta1 as stabilizing factor in human atherosclerotic plaques. Stroke 2004;67:757-65.
11. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, et al., TASC II Working Group. Int Angiol 2007;26(2):81-157.
12. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, et al. ACC/AHA 2005 Practice Guidelkines for the Management of Patients with Periferal Arterial Disease (lower extremity renal mesenteric and abdominal aortic). Circulation 2006;113(11):e463-564.
13. Scorza R, Caronni M, Mascagni B, Berruti V, Bazzi S, Micallet E, Arpaia G, et al. Effect of long-term cycling iloprost therapy in Systemic Sclerosis with raynaud's phenomenon. A randomized, controlled study. Clin Exp Rheumatol 2001;19:503-8. (Pubitemid 32894599)
14. Olschewski H, Hoeper MM, Behr J, Ewert R, Meyer A, Borst MM, Winkler J, et al. Long-term therapy with inhaled iloprost in patients with pulmonary hypertension. Respir Med 2010 Feb 10 [Epub ahead of print].
15. Zulian F, Costantini C, Montesco MC, Schiavon F, Zacchello F. Successful treatment of gangrene in sistemi necrotizing vascu-litis with iloprost. Br J Rheumatol 1998;37:228-30.
16. Meyrier A. Cholesterol crystal embolism: diagnosis and treatment. Kidney Int 2006;69(8):1308-12.
17. Ferrara F, Meli F, Raimondi F, Amato C, Bonura F, Mulè G, Novo G, Novo SS. The treatment of venous leg ulcers. A new therapeutic use of iloprost. Ann Surg 2007;246(5):860-5. (Pubitemid 350035664)
18. Jager M, Tillmann FP, Thomhill TS, Mahmoudi M, Blondin D, Hetzel GR, et al. Rationale for prostaglandin I2 in bone marrow oedema-from theory to application. Arthritis Res Ther 2008;10(5):R120.
19. Mazzone A, Cusa C, Mazzucchelli I, Rosso R, Vezzoli M. Pyoderma gangrenosus complicating ulcerative colitis: an alternative treatment with iloprost. Current Therapeutic Research 1999;60:357-62. (Pubitemid 29408798)
20. Scorza R, Rivolta R, Mascagni B, Berruti V, Bazzi S, Castagnone D, Quarto di Palo F. Effect of iloprost infusion on the resistence index of renal vessels of patients with systemic sclerosis. J Rheumatol 1997;24:1944-8. (Pubitemid 27431926)
21. Knight KR, Lepore DA, O'Brien BM. Interrelationschips between prostanoid and skin flap survival: a review. Prostaglandins Leukot Essent Fatty Acids 1991;44(4):195-200.
22. Duthois S, Cailleux N, Benosman B, Levesque H. tholerance of iloprost and results of treatment of chronic severe lower limb ischaemia in diabetic patients. A retrospective study of 64 consecutive cases. Diabetes Metab 2003;29(1):36-43. (Pubitemid 36362614)
23. Meini S, De Franco V, Auteri A, Setacci C, Di Renzo M, Pieragalli D. Short term effects of one-week treatment with intravenous iloprost in critical limb ischemia patients (lerich Fontaine stage III and IV). Int Angiol 2005;24(1):64-9. (Pubitemid 43933051)
24. Veroux P, Veroux M, Macarrone M, Bonanno MG, Tumminelli MG. Efficacy of a novel method of intravenous infusion of the prostaglandin analogue iloprost for the treatment of lower limb ischemia: an open label, non randomized study in two cohorts. Curr Ther Res Clin Exp 2004;65:255-65. (Pubitemid 39360360)
25. Mazzone A, Vezzoli M, Ottini E, Montagna M, Mazzucchelli I, Dal Canton A. A new method of iloprost administration without a peristaltic pump. Curr Ther Res 2000;61:452-9. (Pubitemid 30602894)
26. Arreghini M, Prudente P, Maglione W, Arnoldi S, Tosi S, Marchesoni A. Tollerabilit̀a, sicurezza ed efficacia del trattamento infusivo con iloprost senza pompa peristaltica in pazienti affetti da sclerosi sistemica. Reumatismo 2001; 53(2):140-4. (Pubitemid 32634226)
27. Hildebrand M, Krause W, Oberender HA, Zurdel-Dillinger S, Junger M, Bodenburg H. Pharmacokinetic of iloprost in patients with severe peripheral arterial occlusive disease. Eicosanoids 1990;3(3):145-8.
28. Milio G, Corrado E, Genova C, Amato C, Raimondi F, Almasio PL, et al. Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life. A new therapeutic protocol. Rheumatology 2006;45(8):999-1004. (Pubitemid 44283056)
29. Duthois S, Cailleux N, Lavesque H. Tolerance and therapeutic results of iloprost in obliterative arteriopathy in lower limbs at the severe chronic ischemia stage. J Mal Vasc 2000;25(1):17-26. (Pubitemid 30148850)